Jefferies analyst, Brandon Couillard, reiterated his Hold rating on shares of Myriad Genetics (NASDAQ: MYGN) even though MYGN posted its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE